Evgen Pharma PLC - Phase 2/3 trial of lead asset SFX-01's potential in reducing severity or preventing the onset of acute respiratory distress syndrome, including in patients with suspected Covid-19, is poised to start recruitment. Notes Pfizer Inc announcement of positive phase 3 Covid-19 vaccine trial analysis.
Chief Executive Huw Jones: "We are pleased to see such progress on a potential vaccine against Covid-19. Recently ARDS has been heavily associated with Covid-19 as it affects the respiratory tract, but it is and will remain a condition in its own right long after we have beaten the pandemic and will continue to be a huge problem for patients. There is a considerable unmet need for effective treatments for ARDS and the outcome of our study will hopefully show how we can use SFX-01 in a serious respiratory condition regardless of the infective agent involved."
Current stock price: 7.95 pence
Year-to-date change: up 13%
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
